Preferred Label : Cergutuzumab Amunaleukin;
NCIt synonyms : CEA-IL-2variant; CEA-IL2v;
NCIt definition : A recombinant fusion protein comprised of cergutuzumab, a genetically engineered human
immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against carcinoembryonic
antigen (CEA, CEACAM5, CD66e), linked to amunaleukin, an engineered, mutated variant
form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic
activities. Upon administration of cergutuzumab amunaleukin, the cergutuzumab moiety
recognizes and binds to CEA, thereby specifically targeting IL-2v to CEA-expressing
tumor tissue. Subsequently, the IL-2v moiety stimulates a local immune response, which
activates both natural killer (NK) cells and cytotoxic T-cells, and eventually leads
to tumor cell killing. CEA is a cell surface protein that is expressed on a wide variety
of cancer cells. The mutations found in IL-2v inhibit its binding to IL-2 receptor-alpha
(CD25, IL2Ra), which prevents the activation of regulatory T-cells (Tregs); however,
IL-2v is able to bind to and induce signaling through IL-2Rbetagamma, which allows
the preferential expansion of NK cells and CD8-positive T-cells. The Fc domain of
cergutuzumab is modified to prevent Fc-gamma binding and downstream effector functions.;
UNII : 48FCG62C25;
CAS number : 1509916-03-3;
Molecule name : RO-6895882; RG-7813;
NCI Metathesaurus CUI : CL539489;
Origin ID : C141459;
UMLS CUI : C4683835;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- concept_is_in_subset
- has_target
